Crossmark

Pharmacokinetic and pharmacodynamic bioequivalence study of a pegfilgrastim biosimilar INTP5 in healthy subjects

Crossref DOI link: https://doi.org/10.1007/s00280-018-3620-x

Published Online: 2018-06-15

Published Print: 2018-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Singh, Inderjeet

Patel, Akash

Patel, Ronak

Jose, Vinu https://orcid.org/0000-0001-6164-0632
Funding

Funding for this research was provided by:

Intas Pharmaceuticals Ltd.
License Information

Text and Data Mining valid from 2018-06-15
More Information

Article History

Received: 4 March 2018

Accepted: 6 June 2018

First Online: 15 June 2018

Compliance with ethical standards

:

: Dr. Inderjeet Singh and Dr. Vinu Jose are employees of Intas Pharmaceutical Ltd., India. Dr. Akash Patel and Mr. Ronak Patel are employees of Lambda Therapeutic Research Ltd., India (CRO).

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

: Informed consent was obtained from all individual participants included in the study.